Tabuk Pharma and Hanmi Pharmaceutical have signed an exclusive license and supply agreement for Rolontis® (Eflapegrastim), an innovative biologic for the treatment of chemotherapy-induced neutropenia, across Saudi Arabia and the MENA region.
This strategic collaboration underscores Tabuk Pharma’s commitment to expanding access to advanced biologics and specialty medicines in alignment with Saudi Vision 2030, contributing to improved patient outcomes and the long-term advancement of regional healthcare.
For more information, please visit the full announcement.
https://www.linkedin.com/posts/tabuk-pharmaceutical-mfg-co_tabuk-pharmaceuticals-x-hanmi-prl-eng-activity-7370794024003215360-P_qj/